Acetyl-TUBA1A (K352) Antibody

What is TUBA1A and why is the K352 acetylation site significant?

TUBA1A (Tubulin Alpha 1A) is a major tubulin isotype that, together with beta-tubulin, forms the building blocks of microtubules . Microtubules are essential cytoskeletal components involved in diverse cellular processes including mitosis, intracellular transport, maintenance of cell shape, and neuronal migration . The K352 (lysine 352) residue is a specific acetylation site located on the outer surface of the microtubule, distinguishing it from the more commonly studied K40 acetylation site which is found in the microtubule lumen . This specific post-translational modification may regulate microtubule stability and protein interactions in unique ways compared to other tubulin modifications.

What are the key properties of commercially available Acetyl-TUBA1A (K352) antibodies?

Based on multiple supplier information, these antibodies share the following characteristics:

These specifications are consistent across multiple suppliers , indicating reliability of the antibody characteristics.

How should I optimize Western blot protocols when using Acetyl-TUBA1A (K352) antibody?

For optimal Western blot results with this antibody:

• Sample preparation: Include deacetylase inhibitors (e.g., trichostatin A, nicotinamide) in lysis buffers to preserve acetylation status.

• Protein loading: Load 20-30 μg of total protein per lane. The observed molecular weight is approximately 50 kDa theoretically, though it may appear at ~68 kDa on gels as noted in some references .

• Blocking: Use 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Begin with the manufacturer's recommended dilution (1:500-1:2000) in blocking buffer. Incubate overnight at 4°C for best results.

• Washing: Perform 3-5 washes with TBST, 5-10 minutes each.

• Detection: Use appropriate HRP-conjugated secondary antibody and ECL detection system.

• Controls: Include samples known to have high acetylation levels (e.g., cells treated with HDAC inhibitors) as positive controls.

What validation methods should I use to confirm antibody specificity?

To ensure the Acetyl-TUBA1A (K352) antibody's specificity:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm binding specificity.

• Acetylation modulation: Compare samples treated with HDAC inhibitors (increased acetylation) versus HDAC6 overexpression (decreased acetylation).

• Genetic approaches: Use cells expressing K352R mutant (prevents acetylation) as a negative control.

• Multiple detection methods: Confirm results using both Western blot and immunofluorescence where possible.

• Cross-validation: Compare results with mass spectrometry-based detection of K352 acetylation.

Validation data provided by manufacturers often includes Western blot analysis in various cell lines, which can serve as reference for expected results .

What are common issues when using this antibody and how can I resolve them?

How should the antibody be stored for maximum stability and performance?

For optimal antibody stability:

• Store at -20°C or -80°C as recommended by manufacturers .

• Upon receipt, make small aliquots (10-20 μl) to avoid repeated freeze-thaw cycles.

• For short-term storage (up to 1 week), 4°C is acceptable for working dilutions .

• Ensure the storage buffer contains preservatives (typically 50% glycerol, 0.02% sodium azide) .

• Centrifuge antibody vial briefly before opening to collect liquid at the bottom.

• Avoid exposing the antibody to direct light for extended periods.

How can I use this antibody to investigate the functional significance of K352 acetylation in neuronal development?

TUBA1A plays a critical role in neuronal development, with mutations associated with brain malformations called "tubulinopathies" . To investigate K352 acetylation in this context:

• Developmental studies: Track acetylation levels during neuronal differentiation, migration, and synaptogenesis using the antibody for Western blot or immunofluorescence.

• Spatial analysis: Examine the subcellular localization of K352-acetylated tubulin in neurons at different developmental stages.

• Mutation studies: Compare K352 acetylation in neurons expressing wild-type versus disease-associated TUBA1A mutations, particularly the R402 mutations mentioned in the literature .

• Functional assessment: Correlate acetylation levels with microtubule stability, dynamics, and motor protein binding through co-localization studies.

• Animal models: Analyze K352 acetylation patterns in mouse models of lissencephaly or other tubulinopathies using the antibody, which has confirmed reactivity to mouse samples .

How does K352 acetylation relate to other post-translational modifications of tubulin?

Tubulin undergoes numerous post-translational modifications (PTMs) that form the "tubulin code":

• Multiple acetylation sites: K352 acetylation occurs in addition to the better-characterized K40 acetylation. Use site-specific antibodies to distinguish between these modifications.

• Coordinated regulation: Investigate whether K352 acetylation correlates with other PTMs like detyrosination, polyglutamylation, or polyglycylation using multiple antibodies on the same samples.

• Differential regulation: K352 and K40 acetylation may be regulated by different deacetylases and acetyltransferases. Design experiments to identify the specific enzymes targeting the K352 site.

• Functional specificity: The external location of K352 (versus luminal K40) suggests different functional roles. Design protein interaction studies to identify binding partners specific to K352-acetylated tubulin.

• Disease relevance: Compare patterns of different tubulin PTMs in disease models, particularly neurodevelopmental disorders linked to TUBA1A mutations .

What advanced techniques can incorporate this antibody beyond standard Western blotting?

Beyond standard applications, consider these advanced techniques:

• Super-resolution microscopy: Use the antibody for STORM or STED microscopy to visualize acetylated microtubule subpopulations with nanometer precision.

• Proximity ligation assay (PLA): Combine with antibodies against potential interaction partners to detect proteins that specifically bind K352-acetylated tubulin.

• ChIP-like approaches: Adapt chromatin immunoprecipitation protocols to isolate microtubule fragments containing K352-acetylated tubulin and identify associated proteins by mass spectrometry.

• Live-cell imaging: Combine with fixation-compatible live-cell imaging approaches to correlate microtubule dynamics with post-fixation identification of K352-acetylated subpopulations.

• Flow cytometry: Optimize for intracellular staining to quantify acetylation levels across cell populations under various conditions.

How does the Acetyl-TUBA1A (K352) antibody compare to other tubulin modification antibodies?

When designing experiments requiring multiple tubulin antibodies, consider host species compatibility for co-staining applications.

What are the current research frontiers involving K352 acetylation of TUBA1A?

Current research areas where this antibody could be valuable include:

• Neurodevelopmental disorders: Investigating the role of K352 acetylation in TUBA1A-associated lissencephaly and other tubulinopathies .

• Cancer biology: Studying how alterations in tubulin acetylation patterns contribute to microtubule dynamics in cancer cells and affect responses to microtubule-targeting drugs.

• Cellular stress responses: Examining how K352 acetylation levels change under various stress conditions and how this affects microtubule stability and function.

• Motor protein interactions: Determining whether K352 acetylation affects binding and processivity of kinesin and dynein motors differently than K40 acetylation.

• Enzyme specificity: Identifying the specific acetyltransferases and deacetylases that regulate K352 acetylation, which may differ from those targeting K40.

What are the recommended best practices for experimental design using this antibody?

When designing experiments with Acetyl-TUBA1A (K352) antibody:

• Include proper controls: Use samples with manipulated acetylation levels (HDAC inhibitor treatment as positive control; HDAC overexpression as negative control).

• Normalize appropriately: When quantifying Western blots, normalize acetylated TUBA1A to total TUBA1A rather than to housekeeping proteins.

• Validate in your system: Perform initial validation in your specific cell types or tissues before proceeding with complex experiments.

• Combine techniques: Complement Western blot data with other techniques such as immunofluorescence or mass spectrometry when possible.

• Report complete methods: Document complete antibody information including catalog number, lot number, dilutions, and incubation conditions in publications.

• Store properly: Maintain antibody aliquots at -20°C or -80°C and avoid repeated freeze-thaw cycles .